Gefitinib in Non Small Cell Lung Cancer

Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Costanzo, Raffaele, Piccirillo, Maria Carmela, Sandomenico, Claudia, Carillio, Guido, Montanino, Agnese, Daniele, Gennaro, Giordano, Pasqualina, Bryce, Jane, De Feo, Gianfranco, Di Maio, Massimo, Rocco, Gaetano, Normanno, Nicola, Perrone, Francesco, Morabito, Alessandro
Format: Artigo
Jezik:Inglês
Izdano: Hindawi Publishing Corporation 2011
Teme:
Review Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3110340/
https://ncbi.nlm.nih.gov/pubmed/21660144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/815269
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items